MRNA stock forecast, quote, news & analysis
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018... Show more
Why Moderna (MRNA) Stock Is Up +138% in the Last 30 Days
Key Takeaways
- Moderna (MRNA) shares gained roughly 138% over the last 30 days, powered by positive Phase 3 melanoma data for its personalized mRNA cancer vaccine.
- The stock posted its largest single-day advance in company history on August 19, 2026, after results with partner Merck (MRK) were announced.
- Over the last quarter, MRNA rose approximately 192%, reflecting a broad re-rating of its oncology pipeline.
- Elevated short interest, estimated near 13.5% of the free float, amplified the rally through short covering.
- Investors are now watching for full trial data, regulatory discussions, and the commercial path for intismeran autogene.
Moderna (MRNA) Company Overview and Market Position
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company built around messenger RNA (mRNA) science. The company develops mRNA-based medicines and vaccines, spanning respiratory vaccines—including its COVID-19 and flu products—and an expanding oncology pipeline. Its most closely watched asset is intismeran autogene, a personalized cancer vaccine being developed in partnership with Merck (MRK) for use alongside the immunotherapy Keytruda. Investors follow MRNA closely because it is a bellwether for whether mRNA technology can succeed beyond its original COVID-19 franchise and into a durable, diversified revenue base.
Moderna (MRNA) Stock Price Performance: Last 30 Days vs. Quarter
Moderna shares climbed from a closing price near $57.92 in late July 2026 to about $137.99 by late August, a gain of roughly 138% over the 30-day window. The move was far from linear: the stock traded in a narrow range in the mid-$50s to low-$60s for most of the period before surging 177% in a single session on August 19, 2026, to close at $174.38. It has since pulled back amid profit-taking and a convertible note offering, though it remains sharply higher on the month.
The quarterly picture is even stronger. From a closing level near $47 in late May 2026, the stock has advanced approximately 192% over the past quarter. Most of that appreciation occurred after the melanoma readout, which marked a decisive shift in how the market values the company's oncology platform.
What Drove MRNA Stock Price in the Last 30 Days
The dominant catalyst was the August 19, 2026 announcement that Moderna and Merck (MRK) reported positive top-line Phase 3 results for intismeran autogene combined with Keytruda in high-risk melanoma. The companies said the combination met its co-primary endpoints of recurrence-free survival and distant metastasis-free survival, describing the results as statistically significant and clinically meaningful. It marked the first late-stage success for a personalized mRNA cancer vaccine.
The news triggered a 177% single-day surge and a historic short squeeze. MRNA had been among the most heavily shorted large-cap stocks, with short interest around 13.5% of the free float, and the rally forced short sellers to cover, adding further upward pressure. The move rippled across the sector, lifting BioNTech (BNTX) and Novavax (NVAX), while analysts including TD Cowen described the data as a "landmark moment." In the days that followed, profit-taking set in, and Moderna announced a convertible note offering of up to $2.3 billion, which contributed to a pullback from the post-announcement peak. Separately, on August 27, 2026, the FDA approved supplemental applications for Moderna's 2026–2027 COVID-19 vaccine formulations.
What Drove MRNA Stock Performance Over the Last Quarter
For most of the quarter, MRNA traded under pressure as its COVID-19 vaccine business continued to decline structurally, keeping the shares in a depressed range. The broader narrative was a company attempting to prove its mRNA platform could extend well beyond infectious disease. Analysts had flagged the melanoma readout as a make-or-break event, and the positive Phase 3 data fundamentally changed that narrative. The result validated a new class of personalized medicine and reframed Moderna as a diversified oncology story, driving a sustained re-rating even after the initial spike cooled.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a much larger universe of hundreds of bots trading thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving traders a filtered view of strategies that are currently generating notable signals. The bots vary widely in strategy, timeframe, and performance metrics, so the section serves as a useful starting point for exploring automated trading approaches across different market conditions. Those interested in systematic, data-driven trading can review the page to compare bots and identify tools that align with their own objectives and risk tolerance.
MRNA Stock Forecast Drivers: What Investors Should Watch Next
Several factors will shape MRNA's path from here. First, the companies have not yet released the full numerical data behind the melanoma results, and detailed findings are expected at an upcoming medical meeting—those details will be key to validating the market's enthusiasm. Second, regulatory discussions and a potential filing are anticipated, with some analysts pointing to possible approval as soon as 2027. Third, intismeran is being studied across multiple additional tumor types, including non-small cell lung cancer, bladder, and renal cell carcinoma, so readouts from those trials could broaden the opportunity. Investors should also monitor the trajectory of the COVID-19 franchise, upcoming earnings, and whether the stock's elevated short interest and valuation lead to continued volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MRNA in upward trend: 10-day moving average crossed above 50-day moving average on August 19, 2026
The 10-day moving average for MRNA crossed bullishly above the 50-day moving average on August 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 07, 2026. You may want to consider a long position or call options on MRNA as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on August 10, 2026. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
MRNA moved above its 50-day moving average on August 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for MRNA moved out of overbought territory on August 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 53 cases where MRNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MRNA broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MRNA entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.905) is normal, around the industry mean (20.183). P/E Ratio (0.000) is within average values for comparable stocks, (27.671). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.520). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (26.882) is also within normal values, averaging (441.890).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative medicines for patients
Industry Biotechnology